Le belimumab n'améliore pas la qualité de vie des patients
RT @Lupusreference: Interesting @cochranecollab systematic review about #belimumab in #lupus: ➡️ Significant improvement in #activity (SRI-…
RT @CochraneLibrary: What are the benefits and risks of belimumab for treating systemic #lupus erythematosus? https://t.co/F54MLYfusv New @…
RT @CochraneLibrary: What are the benefits and risks of belimumab for treating systemic #lupus erythematosus? https://t.co/F54MLYfusv New @…
RT @Lupusreference: Interesting @cochranecollab systematic review about #belimumab in #lupus: ➡️ Significant improvement in #activity (SRI-…
RT @Lupusreference: Interesting @cochranecollab systematic review about #belimumab in #lupus: ➡️ Significant improvement in #activity (SRI-…
RT @CochraneLibrary: What are the benefits and risks of belimumab for treating systemic #lupus erythematosus? https://t.co/F54MLYfusv New @…
RT @Lupusreference: Interesting @cochranecollab systematic review about #belimumab in #lupus: ➡️ Significant improvement in #activity (SRI-…
RT @Lupusreference: Interesting @cochranecollab systematic review about #belimumab in #lupus: ➡️ Significant improvement in #activity (SRI-…
Belimumab for systemic lupus erythematosus - Singh, JA - 2021 | Cochrane Library https://t.co/D3zRgI6pIS
Belimumab para el lupus eritematoso sistémico https://t.co/BQ0axkVROG nueva revisión @CochraneLibrary que analiza la evidencia de 6 estudios que involucraron a un total de 2917 personas de entre 22 y 80 años. https://t.co/l5u1nTaQ7s
Interesting @cochranecollab systematic review about #belimumab in #lupus: ➡️ Significant improvement in #activity (SRI-4) ➡️ Significant improvement in #glucocorticoid dose ➡️ No or only little difference on health‐related #qualityoflife (#HRQOL) Link: htt
RT @CochraneLibrary: What are the benefits and risks of belimumab for treating systemic #lupus erythematosus? https://t.co/F54MLYfusv New @…
RT @CochraneLibrary: What are the benefits and risks of belimumab for treating systemic #lupus erythematosus? https://t.co/F54MLYfusv New @…
What are the benefits and risks of belimumab for treating systemic #lupus erythematosus? https://t.co/F54MLYfusv New @CochraneMSK systematic review looks at the evidence from 6 studies that involved a total of 2917 people aged between 22 and 80 years.
Benefits and risks of belimumab for treating systemic lupus erythematosus ✍️ https://t.co/utZK2VpT5b